Impaired Thiamine Metabolism in Amyotrophic Lateral Sclerosis and Its Potential Treatment With Benfotiamine: A Case Report and a Review of the Literature
- PMID: 37333039
- PMCID: PMC10274516
- DOI: 10.7759/cureus.40511
Impaired Thiamine Metabolism in Amyotrophic Lateral Sclerosis and Its Potential Treatment With Benfotiamine: A Case Report and a Review of the Literature
Abstract
Homogenates of brain tissue from the frontal cortex at autopsy in patients with amyotrophic lateral sclerosis (ALS) showed dramatically reduced levels of the enzyme thiamine pyrophosphatase (TPPase), the enzyme responsible for the conversion of thiamine pyrophosphate (TPP) to thiamine monophosphate (TMP). Additionally, free thiamine (vitamin B1) and TMP levels have been shown to be significantly reduced in the plasma and cerebral spinal fluid (CSF) of patients with ALS. These findings suggest that there is impaired thiamine metabolism in patients with ALS. Impaired thiamine metabolism decreases adenosine triphosphate (ATP) production and is a well-established cause of neurodegeneration. Decreased levels of TPPase, resulting in decreased levels of TMP in the cells of the frontal cortex, might account for the focal neurodegenerative changes observed in motor neurons in ALS. Benfotiamine, a safe, lipid-soluble, highly absorbable thiamine analogue, significantly raises free thiamine, TMP, and TPP levels in the blood. A case in which benfotiamine may have positively impacted the symptoms of a patient with ALS is presented. The use of benfotiamine in patients with ALS appears to be a promising therapeutic option. Considering the severity and the lack of satisfactory treatment options associated with this disease, more research on the effects of benfotiamine on the course of ALS is urgently needed.
Keywords: amyotrophic lateral sclerosis; benfotiamine; motor neuron disease; neurodegeneration; neurodegenerative disease; thiamin; thiamine; thiamine deficiency; vitamin b1; vitamin b1 deficiency.
Copyright © 2023, Mann et al.
Conflict of interest statement
Dr. Mann has filed a provisional patent application with the USPTO on this work.
Figures


Similar articles
-
Synthetic Thioesters of Thiamine: Promising Tools for Slowing Progression of Neurodegenerative Diseases.Int J Mol Sci. 2023 Jul 10;24(14):11296. doi: 10.3390/ijms241411296. Int J Mol Sci. 2023. PMID: 37511056 Free PMC article. Review.
-
Thiamin monophosphate in the CSF of patients with amyotrophic lateral sclerosis.Arch Neurol. 1982 Aug;39(8):507-9. doi: 10.1001/archneur.1982.00510200049009. Arch Neurol. 1982. PMID: 7103799
-
Thiamine and benfotiamine: Focus on their therapeutic potential.Heliyon. 2023 Nov 7;9(11):e21839. doi: 10.1016/j.heliyon.2023.e21839. eCollection 2023 Nov. Heliyon. 2023. PMID: 38034619 Free PMC article. Review.
-
Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice.Brain. 2010 May;133(Pt 5):1342-51. doi: 10.1093/brain/awq069. Epub 2010 Apr 12. Brain. 2010. PMID: 20385653
-
Inversion of T/TMP ratio in ALS: a specific finding?Ital J Neurol Sci. 1986 Jun;7(3):333-5. doi: 10.1007/BF02340871. Ital J Neurol Sci. 1986. PMID: 3015835
Cited by
-
Microbiome and micronutrient in ALS: From novel mechanisms to new treatments.Neurotherapeutics. 2024 Oct;21(6):e00441. doi: 10.1016/j.neurot.2024.e00441. Epub 2024 Aug 31. Neurotherapeutics. 2024. PMID: 39218769 Free PMC article. Review.
-
Cognitive capacity in amyotrophic lateral sclerosis: the value of diagnostic markers in cerebrospinal fluid and the influence of nutrition and pulmonary function.Brain Commun. 2025 Apr 8;7(2):fcaf137. doi: 10.1093/braincomms/fcaf137. eCollection 2025. Brain Commun. 2025. PMID: 40241787 Free PMC article.
-
Synthetic Thioesters of Thiamine: Promising Tools for Slowing Progression of Neurodegenerative Diseases.Int J Mol Sci. 2023 Jul 10;24(14):11296. doi: 10.3390/ijms241411296. Int J Mol Sci. 2023. PMID: 37511056 Free PMC article. Review.
-
Medication use and risk of amyotrophic lateral sclerosis: using machine learning for an exposome-wide screen of a large clinical database.Amyotroph Lateral Scler Frontotemporal Degener. 2024 May;25(3-4):367-375. doi: 10.1080/21678421.2024.2320878. Epub 2024 Mar 1. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38426489 Free PMC article.
References
-
- Tricarboxylic acid cycle enzymes following thiamine deficiency. Bubber P, Ke ZJ, Gibson GE. Neurochem Int. 2004;45:1021–1028. - PubMed
-
- Thiamine (vitamin B1) Fattal-Valevski A. J Evid Based Complementary Altern Med. 2011;16:12–20.
-
- Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. Latt N, Dore G. Intern Med J. 2014;44:911–915. - PubMed
-
- Low thiamine diphosphate levels in brains of patients with frontal lobe degeneration of the non-Alzheimer's type. Bettendorff L, Mastrogiacomo F, Wins P, Kish SJ, Grisar T, Ball MJ. J Neurochem. 1997;69:2005–2010. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous